AC025262.1 | Mesenchymal stem cell protein DSC96; Uncharacterized protein | | | | | | Tissue enriched |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ACTA1 | Actin, alpha 1, skeletal muscle | Cytoskeleton related proteins Disease related genes Plasma proteins
| | | | | Tissue enriched |
ADCK3 | AarF domain containing kinase 3 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| | | | | Tissue enriched |
ADSSL1 | Adenylosuccinate synthase like 1 | Enzymes Plasma proteins
| | | | | Tissue enriched |
AGL | Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Tissue enriched |
AMPD1 | Adenosine monophosphate deaminase 1 | Disease related genes Enzymes Potential drug targets Predicted secreted proteins
| | | | | Tissue enriched |
ANKRD23 | Ankyrin repeat domain 23 | | | | | | Tissue enriched |
ART1 | ADP-ribosyltransferase 1 | CD markers Enzymes Predicted membrane proteins
| | | | | Tissue enriched |
ASB10 | Ankyrin repeat and SOCS box containing 10 | Disease related genes
| | | | | Tissue enriched |
ASB12 | Ankyrin repeat and SOCS box containing 12 | | | | | | Tissue enriched |
ASB14 | Ankyrin repeat and SOCS box containing 14 | | | | | | Tissue enriched |
ASB16 | Ankyrin repeat and SOCS box containing 16 | | | | | | Tissue enriched |
ATP1B4 | ATPase, Na+/K+ transporting, beta 4 polypeptide | Predicted membrane proteins
| | | | | Tissue enriched |
ATP2A1 | ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Tissue enriched |
BIN1 | Bridging integrator 1 | Disease related genes
| | | | | Tissue enriched |
C20orf166 | Chromosome 20 open reading frame 166 | | | | | | Tissue enriched |
C8orf22 | Chromosome 8 open reading frame 22 | | | | | | Tissue enriched |
CA3 | Carbonic anhydrase III, muscle specific | Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNB1 | Calcium channel, voltage-dependent, beta 1 subunit | FDA approved drug targets
| | | | | Tissue enriched |
CACNG1 | Calcium channel, voltage-dependent, gamma subunit 1 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CALML6 | Calmodulin-like 6 | RAS pathway related proteins
| | | | | Tissue enriched |
CASQ1 | Calsequestrin 1 (fast-twitch, skeletal muscle) | Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enriched |
CDH15 | Cadherin 15, type 1, M-cadherin (myotubule) | Disease related genes Predicted membrane proteins
| | | | | Tissue enriched |
CHRNA10 | Cholinergic receptor, nicotinic, alpha 10 (neuronal) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
CHRND | Cholinergic receptor, nicotinic, delta (muscle) | Disease related genes Potential drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
CHRNG | Cholinergic receptor, nicotinic, gamma (muscle) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
CLCN1 | Chloride channel, voltage-sensitive 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
DCD | Dermcidin | Plasma proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
DDIT4L | DNA-damage-inducible transcript 4-like | | | | | | Tissue enriched |
DUPD1 | Dual specificity phosphatase and pro isomerase domain containing 1 | Enzymes
| | | | | Tissue enriched |
DUSP13 | Dual specificity phosphatase 13 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ENO3 | Enolase 3 (beta, muscle) | Candidate cardiovascular disease genes Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enriched |
FBP2 | Fructose-1,6-bisphosphatase 2 | Enzymes Plasma proteins
| | | | | Tissue enriched |
FEM1A | Fem-1 homolog a (C. elegans) | | | | | | Tissue enriched |
FGF6 | Fibroblast growth factor 6 | Cancer-related genes RAS pathway related proteins
| | | | | Tissue enriched |
FHL3 | Four and a half LIM domains 3 | | | | | | Tissue enriched |
GADL1 | Glutamate decarboxylase-like 1 | Enzymes
| | | | | Tissue enriched |
IDI2 | Isopentenyl-diphosphate delta isomerase 2 | Enzymes
| | | | | Tissue enriched |
JPH1 | Junctophilin 1 | Predicted membrane proteins
| | | | | Tissue enriched |
JSRP1 | Junctional sarcoplasmic reticulum protein 1 | Predicted secreted proteins
| | | | | Tissue enriched |
KBTBD13 | Kelch repeat and BTB (POZ) domain containing 13 | Disease related genes
| | | | | Tissue enriched |
KCNA7 | Potassium voltage-gated channel, shaker-related subfamily, member 7 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ11 | Potassium inwardly-rectifying channel, subfamily J, member 11 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ12 | Potassium inwardly-rectifying channel, subfamily J, member 12 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KLHL33 | Kelch-like family member 33 | | | | | | Tissue enriched |
KLHL34 | Kelch-like family member 34 | | | | | | Tissue enriched |
KLHL40 | Kelch-like family member 40 | Disease related genes
| | | | | Tissue enriched |